Natpara Disease Interactions

Patients known to have an underlying hypercalcemic disorder, such as primary hyperparathyroidism, should not be treated with parathyroid hormone and its analogs because of the risk of exacerbating hypercalcemia.

Parathyroid hormone and its analogs should not be used in patients who are at increased baseline risk for osteosarcoma. These agents should only be used if the potential benefits are considered to outweigh the potential risks. Monitor these patients according to clinical guidelines. Patients with bone metastases or a history of skeletal malignancies should not be treated with these agents.

Parathyroid hormone is eliminated by the kidney and maximum drug levels increased with renal impairment. No dose adjustment is recommended in patients with mild to moderate renal impairment. No studies have been conducted in patients with severe renal impairment or in renal impairment patients on dialysis. Care and close monitoring should be exercised when using this agent in patients with severe renal impairment or on dialysis.